Literature DB >> 9076425

Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours.

M den Ouden1, J M Ubachs, J E Stoot, J W van Wersch.   

Abstract

OBJECTIVE: The purpose of the study was to determine whether ovarian cancer patients had haematological anomalies compared to patients with benign ovarian tumours. STUDY
DESIGN: Whole blood cell counts and leucocyte differentials were measured in 70 patients suspected of having ovarian tumours. Postoperatively, 20 patients had metastatic ovarian cancer and 50 patients had benign ovarian tumours. A control group consisted of 39 healthy women. Cell counting was performed by the Sysmex NE-8,000 system. The significance of differences was assessed by the Mann-Whitney U-test or the chi 2-test, where appropriate.
RESULTS: The median haemoglobin and haematocrit levels were significantly lower (P-values 0.004 and 0.02, respectively) and the platelet count was higher (P = 0.02) in the malignant group compared with the benign group. The leucocyte differentials revealed significantly lower values for lymphocytes in the malignant group in comparison to the design and control groups (P-values 0.02 and 0.00005, respectively). A significant increase in monocytes (P = 0.002) and decreases in eosinophils and basophils (P-values 0.04 and 0.02, respectively) were found in the malignant group compared to the benign group.
CONCLUSION: These results demonstrate significant changes in whole blood cell counts and leucocyte differentials in patients with ovarian cancer. The low lymphocyte counts in the malignant group possibly indicate a primary immunodeficiency as a casual factor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9076425     DOI: 10.1016/s0301-2115(96)02662-0

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  9 in total

1.  Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer.

Authors:  Viren Asher; Joanne Lee; Anni Innamaa; Anish Bali
Journal:  Clin Transl Oncol       Date:  2011-07       Impact factor: 3.405

2.  Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis.

Authors:  Yanlin Luo; Hee Seung Kim; Miseon Kim; Maria Lee; Yong Sang Song
Journal:  J Gynecol Oncol       Date:  2017-03-07       Impact factor: 4.401

3.  Platelet count as a biomarker for monitoring treatment response and disease recurrence in recurrent epithelial ovarian cancer.

Authors:  Qinghong Hu; Abha Hada; Liping Han
Journal:  J Ovarian Res       Date:  2020-07-18       Impact factor: 4.234

4.  Mendelian randomization analysis of the association between human blood cell traits and uterine polyps.

Authors:  Shuliu Sun; Yan Liu; Lanlan Li; Minjie Jiao; Yufen Jiang; Beilei Li; Wenrong Gao; Xiaojuan Li
Journal:  Sci Rep       Date:  2021-03-04       Impact factor: 4.379

5.  Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer.

Authors:  Supachai Raungkaewmanee; Siriwan Tangjitgamol; Sumonmal Manusirivithaya; Sunamchok Srijaipracharoen; Thaovalai Thavaramara
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

6.  DNA methylation arrays as surrogate measures of cell mixture distribution.

Authors:  Eugene Andres Houseman; William P Accomando; Devin C Koestler; Brock C Christensen; Carmen J Marsit; Heather H Nelson; John K Wiencke; Karl T Kelsey
Journal:  BMC Bioinformatics       Date:  2012-05-08       Impact factor: 3.169

7.  Parameters of blood count and tumor markers in patients with borderline ovarian tumors: a retrospective analysis and relation to staging.

Authors:  Rosekeila Simões Nomelini; Taísa Morete da Silva; Beatriz Martins Tavares Murta; Eddie Fernando Candido Murta
Journal:  ISRN Oncol       Date:  2012-04-17

8.  Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer.

Authors:  Devin C Koestler; Prabhakar Chalise; Mine S Cicek; Julie M Cunningham; Sebastian Armasu; Melissa C Larson; Jeremy Chien; Matthew Block; Kimberly R Kalli; Thomas A Sellers; Brooke L Fridley; Ellen L Goode
Journal:  BMC Med Genomics       Date:  2014-01-30       Impact factor: 3.063

9.  Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study.

Authors:  Hee Seung Kim; Hwa-Young Choi; Maria Lee; Dong Hoon Suh; Kidong Kim; Jae Hong No; Hyun Hoon Chung; Yong Beom Kim; Yong Sang Song
Journal:  Cancer Res Treat       Date:  2015-03-06       Impact factor: 4.679

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.